Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report
-
By
-
Maja Machulak
-
Magdalena Zwierzchowska
-
Kinga Łysak
-
Kamil Kośmider
-
Katarzyna Szklener
-
Magdalena Skórzewska
-
May 25, 2026
-
Clinical Scorecard: Remarkable Efficacy of Everolimus in Treating Recurrent Endometrioid Adenocarcinoma Lacking NF1: A Case Study
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Loss-of-function mutation in NF1 gene; mTOR pathway inhibition (source needed) |
| Target Population | Women with recurrent endometrioid adenocarcinoma (source needed) |
| Care Setting | |
Key Highlights
- Patient achieved complete remission with everolimus after recurrence of endometrial cancer.
- Significant metabolic toxicity observed, including severe dyslipidemia.
- First case report demonstrating mutation-driven therapeutic decision in this context.
- Everolimus monotherapy led to durable clinical benefit.
Guideline-Based Recommendations
Diagnosis
Management
- Off-label use of everolimus for targeted therapy based on molecular profile (source needed).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
64-year-old woman with grade I endometrioid adenocarcinoma, stage IA.
Everolimus resulted in complete remission but required management of metabolic side effects.
Clinical Best Practices
Related Resources & Content
